{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T13:50:00Z","timestamp":1790776200625,"version":"4.1.0"},"reference-count":61,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,4,14]],"date-time":"2023-04-14T00:00:00Z","timestamp":1681430400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,4,14]],"date-time":"2023-04-14T00:00:00Z","timestamp":1681430400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100000925","name":"Department of Health | National Health and Medical Research Council","doi-asserted-by":"publisher","award":["1088703"],"award-info":[{"award-number":["1088703"]}],"id":[{"id":"10.13039\/501100000925","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000925","name":"Department of Health | National Health and Medical Research Council","doi-asserted-by":"publisher","award":["2003575"],"award-info":[{"award-number":["2003575"]}],"id":[{"id":"10.13039\/501100000925","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000926","name":"Leukaemia Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000926","id-type":"DOI","asserted-by":"publisher"}]},{"name":"CSL Centenary Fellowship (SWL), Herron Family Trust, Gordon and Jessie Gilmour"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Commun"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    Acute myeloid leukemia (AML) is a genetically heterogeneous, aggressive hematological malignancy induced by distinct oncogenic driver mutations. The effect of specific AML oncogenes on immune activation or suppression is unclear. Here, we examine immune responses in genetically distinct models of AML and demonstrate that specific AML oncogenes dictate immunogenicity, the quality of immune response and immune escape through immunoediting. Specifically, expression of Nras\n                    <jats:sup>G12D<\/jats:sup>\n                    alone is sufficient to drive a potent anti-leukemia response through increased MHC Class II expression that can be overcome with increased expression of Myc. These data have important implications for the design and implementation of personalized immunotherapies for patients with AML.\n                  <\/jats:p>","DOI":"10.1038\/s41467-023-37592-9","type":"journal-article","created":{"date-parts":[[2023,4,14]],"date-time":"2023-04-14T14:02:18Z","timestamp":1681480938000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":17,"title":["Oncogenic drivers dictate immune control of acute myeloid leukemia"],"prefix":"10.1038","volume":"14","author":[{"given":"Rebecca J.","family":"Austin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1748-0659","authenticated-orcid":false,"given":"Jasmin","family":"Straube","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rohit","family":"Halder","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yashaswini","family":"Janardhanan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claudia","family":"Bruedigam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1434-4288","authenticated-orcid":false,"given":"Matthew","family":"Witkowski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leanne","family":"Cooper","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amy","family":"Porter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthias","family":"Braun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fernando","family":"Souza-Fonseca-Guimaraes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simone A.","family":"Minnie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emily","family":"Cooper","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sebastien","family":"Jacquelin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Axia","family":"Song","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tobias","family":"Bald","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6631-9028","authenticated-orcid":false,"given":"Kyohei","family":"Nakamura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Geoffrey R.","family":"Hill","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Iannis","family":"Aifantis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8050-6209","authenticated-orcid":false,"given":"Steven W.","family":"Lane","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7466-6927","authenticated-orcid":false,"given":"Megan J.","family":"Bywater","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,4,14]]},"reference":[{"key":"37592_CR1","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1016\/j.semcancer.2009.12.001","volume":"20","author":"SW Lane","year":"2010","unstructured":"Lane, S. W. & Gilliland, D. G. Leukemia stem cells. Semin. Cancer Biol. 20, 71\u201376 (2010).","journal-title":"Semin. Cancer Biol."},{"key":"37592_CR2","doi-asserted-by":"publisher","first-page":"2209","DOI":"10.1056\/NEJMoa1516192","volume":"374","author":"E Papaemmanuil","year":"2016","unstructured":"Papaemmanuil, E. et al. Genomic classification and prognosis in acute myeloid leukemia. N. Engl. J. Med. 374, 2209\u20132221 (2016).","journal-title":"N. Engl. J. Med."},{"key":"37592_CR3","doi-asserted-by":"publisher","first-page":"1136","DOI":"10.1056\/NEJMra1406184","volume":"373","author":"H D\u00f6hner","year":"2015","unstructured":"D\u00f6hner, H., Weisdorf, D. J. & Bloomfield, C. D. Acute myeloid leukemia. N. Engl. J. Med. 373, 1136\u20131152 (2015).","journal-title":"N. Engl. J. Med."},{"key":"37592_CR4","doi-asserted-by":"publisher","first-page":"1148","DOI":"10.1182\/blood-2017-09-807438","volume":"131","author":"J Straube","year":"2018","unstructured":"Straube, J., Ling, V. Y., Hill, G. R. & Lane, S. W. The impact of age, NPM1(mut), and FLT3(ITD) allelic ratio in patients with acute myeloid leukemia. Blood 131, 1148\u20131153 (2018).","journal-title":"Blood"},{"key":"37592_CR5","doi-asserted-by":"publisher","first-page":"617","DOI":"10.1056\/NEJMoa2012971","volume":"383","author":"CD DiNardo","year":"2020","unstructured":"DiNardo, C. D. et al. Azacitidine and venetoclax in previously untreated acute myeloid leukemia. N. Engl. J. Med. 383, 617\u2013629 (2020).","journal-title":"N. Engl. J. Med."},{"key":"37592_CR6","doi-asserted-by":"publisher","first-page":"2680","DOI":"10.1182\/blood.V85.10.2680.bloodjournal85102680","volume":"85","author":"M Bocchia","year":"1995","unstructured":"Bocchia, M. et al. Specific binding of leukemia oncogene fusion protein peptides to HLA class I molecules. Blood 85, 2680\u20132684 (1995).","journal-title":"Blood"},{"key":"37592_CR7","first-page":"1042","volume":"90","author":"JL Pollock","year":"2005","unstructured":"Pollock, J. L., Lane, A. A., Schrimpf, K. & Ley, T. J. Murine acute promyelocytic leukemia cells can be recognized and cleared in vivo by adaptive immune mechanisms. Haematologica 90, 1042\u20131049 (2005).","journal-title":"Haematologica"},{"key":"37592_CR8","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1016\/j.critrevonc.2016.04.020","volume":"103","author":"R Austin","year":"2016","unstructured":"Austin, R., Smyth, M. J. & Lane, S. W. Harnessing the immune system in acute myeloid leukaemia. Crit. Rev. Oncol.\/Hematol. 103, 62\u201377 (2016).","journal-title":"Crit. Rev. Oncol.\/Hematol."},{"key":"37592_CR9","doi-asserted-by":"publisher","first-page":"2019","DOI":"10.1038\/leu.2012.87","volume":"26","author":"E Lion","year":"2012","unstructured":"Lion, E., Willemen, Y., Berneman, Z. N., Van Tendeloo, V. F. & Smits, E. L. Natural killer cell immune escape in acute myeloid leukemia. Leukemia 26, 2019\u20132026 (2012).","journal-title":"Leukemia"},{"key":"37592_CR10","doi-asserted-by":"publisher","DOI":"10.1186\/2051-1426-1-13","volume":"1","author":"R Teague","year":"2013","unstructured":"Teague, R. & Kline, J. Immune evasion in acute myeloid leukemia: current concepts and future directions. J. Immunother. Cancer 1, 13 (2013).","journal-title":"J. Immunother. Cancer"},{"key":"37592_CR11","doi-asserted-by":"publisher","first-page":"603","DOI":"10.1038\/s41591-019-0400-z","volume":"25","author":"C Toffalori","year":"2019","unstructured":"Toffalori, C. et al. Immune signature drives leukemia escape and relapse after hematopoietic cell transplantation. Nat. Med. 25, 603\u2013611 (2019).","journal-title":"Nat. Med."},{"key":"37592_CR12","doi-asserted-by":"publisher","first-page":"1265","DOI":"10.1016\/j.cell.2019.01.031","volume":"176","author":"P van Galen","year":"2019","unstructured":"van Galen, P. et al. Single-Cell RNA-Seq Reveals AML Hierarchies Relevant to Disease Progression and Immunity. Cell 176, 1265\u20131281 e1224 (2019).","journal-title":"Cell"},{"key":"37592_CR13","doi-asserted-by":"publisher","first-page":"E219","DOI":"10.1002\/ajh.24179","volume":"90","author":"VY Ling","year":"2015","unstructured":"Ling, V. Y. et al. Immunological markers for prognostication in cytogenetically normal acute myeloid leukemia. Am. J. Hematol. 90, E219\u2013E220 (2015).","journal-title":"Am. J. Hematol."},{"key":"37592_CR14","doi-asserted-by":"publisher","first-page":"3661","DOI":"10.1182\/blood.V99.10.3661","volume":"99","author":"RT Costello","year":"2002","unstructured":"Costello, R. T. et al. Defective expression and function of natural killer cell-triggering receptors in patients with acute myeloid leukemia. Blood 99, 3661\u20133667 (2002).","journal-title":"Blood"},{"key":"37592_CR15","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1182\/blood-2005-08-027979","volume":"109","author":"C Fauriat","year":"2007","unstructured":"Fauriat, C. et al. Deficient expression of NCR in NK cells from acute myeloid leukemia: evolution during leukemia treatment and impact of leukemia cells in NCRdull phenotype induction. Blood 109, 323\u2013330 (2007).","journal-title":"Blood"},{"key":"37592_CR16","doi-asserted-by":"publisher","first-page":"1195","DOI":"10.1007\/s00262-011-1050-2","volume":"60","author":"B Sanchez-Correa","year":"2011","unstructured":"Sanchez-Correa, B. et al. Human NK cells in acute myeloid leukaemia patients: analysis of NK cell-activating receptors and their ligands. Cancer Immunol. Immunother. 60, 1195\u20131205 (2011).","journal-title":"Cancer Immunol. Immunother."},{"key":"37592_CR17","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1007\/s00262-009-0724-5","volume":"59","author":"MJ Szczepanski","year":"2010","unstructured":"Szczepanski, M. J. et al. Interleukin-15 enhances natural killer cell cytotoxicity in patients with acute myeloid leukemia by upregulating the activating NK cell receptors. Cancer Immunol. Immunother. 59, 73\u201379 (2010).","journal-title":"Cancer Immunol. Immunother."},{"key":"37592_CR18","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1038\/sj.leu.2404032","volume":"20","author":"D Behl","year":"2006","unstructured":"Behl, D. et al. Absolute lymphocyte count recovery after induction chemotherapy predicts superior survival in acute myelogenous leukemia. Leukemia 20, 29\u201334 (2006).","journal-title":"Leukemia"},{"key":"37592_CR19","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1111\/j.1600-0609.2004.00248.x","volume":"73","author":"CI Muller","year":"2004","unstructured":"Muller, C. I. et al. Hematologic and molecular spontaneous remission following sepsis in acute monoblastic leukemia with translocation (9;11): a case report and review of the literature. Eur. J. Haematol. 73, 62\u201366 (2004).","journal-title":"Eur. J. Haematol."},{"key":"37592_CR20","doi-asserted-by":"publisher","first-page":"370","DOI":"10.1158\/2159-8290.CD-18-0774","volume":"9","author":"N Daver","year":"2019","unstructured":"Daver, N. et al. Efficacy, Safety, and Biomarkers of Response to Azacitidine and Nivolumab in Relapsed\/Refractory Acute Myeloid Leukemia: A Nonrandomized, Open-Label, Phase II Study. Cancer Discov. 9, 370\u2013383 (2019).","journal-title":"Cancer Discov."},{"key":"37592_CR21","first-page":"330","volume":"136","author":"D Sallman","year":"2020","unstructured":"Sallman, D. et al. The first-in-class anti-CD47 antibody magrolimab combined with azacitidine is well-tolerated and effective in AML patients: phase 1b results. Blood 136, 330 (2020).","journal-title":"Blood"},{"key":"37592_CR22","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1038\/nature12477","volume":"500","author":"LB Alexandrov","year":"2013","unstructured":"Alexandrov, L. B. et al. Signatures of mutational processes in human cancer. Nature 500, 415\u2013421 (2013).","journal-title":"Nature"},{"key":"37592_CR23","doi-asserted-by":"publisher","first-page":"453","DOI":"10.1182\/blood-2014-04-567933","volume":"124","author":"M Rajasagi","year":"2014","unstructured":"Rajasagi, M. et al. Systematic identification of personal tumor-specific neoantigens in chronic lymphocytic leukemia. Blood 124, 453\u2013462 (2014).","journal-title":"Blood"},{"key":"37592_CR24","doi-asserted-by":"publisher","DOI":"10.1038\/bcj.2016.50","volume":"6","author":"I De Kouchkovsky","year":"2016","unstructured":"De Kouchkovsky, I. & Abdul-Hay, M. Acute myeloid leukemia: a comprehensive review and 2016 update. Blood Cancer J. 6, e441 (2016).","journal-title":"Blood Cancer J."},{"key":"37592_CR25","doi-asserted-by":"publisher","first-page":"424","DOI":"10.1182\/blood-2016-08-733196","volume":"129","author":"H Dohner","year":"2017","unstructured":"Dohner, H. et al. Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel. Blood 129, 424\u2013447 (2017).","journal-title":"Blood"},{"key":"37592_CR26","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1016\/j.coi.2014.01.004","volume":"27","author":"D Mittal","year":"2014","unstructured":"Mittal, D., Gubin, M. M., Schreiber, R. D. & Smyth, M. J. New insights into cancer immunoediting and its three component phases-elimination, equilibrium and escape. Curr. Opin. Immunol. 27, 16\u201325 (2014).","journal-title":"Curr. Opin. Immunol."},{"key":"37592_CR27","doi-asserted-by":"publisher","first-page":"1565","DOI":"10.1126\/science.1203486","volume":"331","author":"RD Schreiber","year":"2011","unstructured":"Schreiber, R. D., Old, L. J. & Smyth, M. J. Cancer immunoediting: integrating immunity\u2019s roles in cancer suppression and promotion. Science 331, 1565\u20131570 (2011).","journal-title":"Science"},{"key":"37592_CR28","doi-asserted-by":"publisher","first-page":"533","DOI":"10.1089\/107999099313983","volume":"19","author":"F Mazurier","year":"1999","unstructured":"Mazurier, F. et al. A novel immunodeficient mouse model-RAG2 x common cytokine receptor gamma chain double mutants-requiring exogenous cytokine administration for human hematopoietic stem cell engraftment. J. Interferon Cytokine Res. 19, 533\u2013541 (1999).","journal-title":"J. Interferon Cytokine Res."},{"key":"37592_CR29","doi-asserted-by":"publisher","first-page":"131","DOI":"10.3324\/haematol.13299","volume":"94","author":"RG Verhaak","year":"2009","unstructured":"Verhaak, R. G. et al. Prediction of molecular subtypes in acute myeloid leukemia based on gene expression profiling. Haematologica 94, 131\u2013134 (2009).","journal-title":"Haematologica"},{"key":"37592_CR30","doi-asserted-by":"publisher","unstructured":"Lasry, A. et al. An inflammatory state remodels the immune microenvironment and improves risk stratification in acute myeloid leukemia. Nat. Cancer https:\/\/doi.org\/10.1038\/s43018-022-00480-0 (2022).","DOI":"10.1038\/s43018-022-00480-0"},{"key":"37592_CR31","doi-asserted-by":"publisher","first-page":"1911","DOI":"10.1182\/blood-2017-01-760595","volume":"130","author":"OM Dovey","year":"2017","unstructured":"Dovey, O. M. et al. Molecular synergy underlies the co-occurrence patterns and phenotype of NPM1-mutant acute myeloid leukemia. Blood 130, 1911\u20131922 (2017).","journal-title":"Blood"},{"key":"37592_CR32","doi-asserted-by":"publisher","first-page":"485","DOI":"10.1016\/j.ccr.2010.10.002","volume":"18","author":"K Rakhra","year":"2010","unstructured":"Rakhra, K. et al. CD4+ T cells contribute to the remodeling of the microenvironment required for sustained tumor regression upon oncogene inactivation. Cancer Cell 18, 485\u2013498 (2010).","journal-title":"Cancer Cell"},{"key":"37592_CR33","doi-asserted-by":"publisher","first-page":"1301","DOI":"10.1016\/j.cell.2017.11.013","volume":"171","author":"RM Kortlever","year":"2017","unstructured":"Kortlever, R. M. et al. Myc cooperates with Ras by programming inflammation and immune suppression. Cell 171, 1301\u20131315.e1314 (2017).","journal-title":"Cell"},{"key":"37592_CR34","doi-asserted-by":"publisher","first-page":"711","DOI":"10.1056\/NEJMoa1003466","volume":"363","author":"FS Hodi","year":"2010","unstructured":"Hodi, F. S. et al. Improved survival with ipilimumab in patients with metastatic melanoma. N. Engl. J. Med. 363, 711\u2013723 (2010).","journal-title":"N. Engl. J. Med."},{"key":"37592_CR35","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1126\/science.aac9935","volume":"352","author":"SC Casey","year":"2016","unstructured":"Casey, S. C. et al. MYC regulates the antitumor immune response through CD47 and PD-L1. Science 352, 227\u2013231 (2016).","journal-title":"Science"},{"key":"37592_CR36","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-020-15552-x","volume":"11","author":"MJ Bywater","year":"2020","unstructured":"Bywater, M. J. et al. Reactivation of Myc transcription in the mouse heart unlocks its proliferative capacity. Nat. Commun. 11, 1827 (2020).","journal-title":"Nat. Commun."},{"key":"37592_CR37","doi-asserted-by":"publisher","first-page":"380","DOI":"10.1016\/j.ccell.2020.06.002","volume":"38","author":"O Dufva","year":"2020","unstructured":"Dufva, O. et al. Immunogenomic landscape of hematological malignancies. Cancer Cell 38, 380\u2013399.e313 (2020).","journal-title":"Cancer Cell"},{"key":"37592_CR38","doi-asserted-by":"publisher","first-page":"429","DOI":"10.1016\/0008-8749(91)90091-O","volume":"137","author":"AS Freedman","year":"1991","unstructured":"Freedman, A. S., Freeman, G. J., Rhynhart, K. & Nadler, L. M. Selective induction of B7\/BB-1 on interferon-gamma stimulated monocytes: a potential mechanism for amplification of T cell activation through the CD28 pathway. Cell Immunol. 137, 429\u2013437 (1991).","journal-title":"Cell Immunol."},{"key":"37592_CR39","doi-asserted-by":"publisher","first-page":"111104","DOI":"10.1016\/j.celrep.2022.111104","volume":"40","author":"RE Reggiardo","year":"2022","unstructured":"Reggiardo, R. E. et al. Mutant KRAS regulates transposable element RNA and innate immunity via KRAB zinc-finger genes. Cell Rep. 40, 111104 (2022).","journal-title":"Cell Rep."},{"key":"37592_CR40","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1016\/j.immuni.2018.03.004","volume":"48","author":"MD Wellenstein","year":"2018","unstructured":"Wellenstein, M. D. & de Visser, K. E. Cancer-cell-intrinsic mechanisms shaping the tumor immune landscape. Immunity 48, 399\u2013416 (2018).","journal-title":"Immunity"},{"key":"37592_CR41","doi-asserted-by":"publisher","first-page":"400","DOI":"10.1038\/nature10755","volume":"482","author":"H Matsushita","year":"2012","unstructured":"Matsushita, H. et al. Cancer exome analysis reveals a T-cell-dependent mechanism of cancer immunoediting. Nature 482, 400\u2013404 (2012).","journal-title":"Nature"},{"key":"37592_CR42","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1038\/nature10803","volume":"482","author":"M DuPage","year":"2012","unstructured":"DuPage, M., Mazumdar, C., Schmidt, L. M., Cheung, A. F. & Jacks, T. Expression of tumour-specific antigens underlies cancer immunoediting. Nature 482, 405 (2012).","journal-title":"Nature"},{"key":"37592_CR43","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms14607","volume":"8","author":"K Takeda","year":"2017","unstructured":"Takeda, K. et al. IFN-\u03b3 is required for cytotoxic T cell-dependent cancer genome immunoediting. Nat. Commun. 8, 14607 (2017).","journal-title":"Nat. Commun."},{"key":"37592_CR44","doi-asserted-by":"publisher","first-page":"1107","DOI":"10.1038\/35074122","volume":"410","author":"V Shankaran","year":"2001","unstructured":"Shankaran, V. et al. IFNgamma and lymphocytes prevent primary tumour development and shape tumour immunogenicity. Nature 410, 1107\u20131111 (2001).","journal-title":"Nature"},{"key":"37592_CR45","doi-asserted-by":"publisher","first-page":"1219","DOI":"10.1158\/2159-8290.CD-18-0442","volume":"8","author":"RG Majzner","year":"2018","unstructured":"Majzner, R. G. & Mackall, C. L. Tumor antigen escape from CAR T-cell therapy. Cancer Discov. 8, 1219\u20131226 (2018).","journal-title":"Cancer Discov."},{"key":"37592_CR46","doi-asserted-by":"publisher","first-page":"412","DOI":"10.1046\/j.1365-2141.2002.03843.x","volume":"119","author":"GA Kennedy","year":"2002","unstructured":"Kennedy, G. A. et al. Incidence and nature of CD20-negative relapses following rituximab therapy in aggressive B-cell non-Hodgkin\u2019s lymphoma: a retrospective review. Br. J. Haematol. 119, 412\u2013416 (2002).","journal-title":"Br. J. Haematol."},{"key":"37592_CR47","doi-asserted-by":"publisher","first-page":"2330","DOI":"10.1056\/NEJMoa1808777","volume":"379","author":"MJ Christopher","year":"2018","unstructured":"Christopher, M. J. et al. Immune escape of relapsed AML cells after allogeneic transplantation. N. Engl. J. Med. 379, 2330\u20132341 (2018).","journal-title":"N. Engl. J. Med."},{"key":"37592_CR48","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-019-50111-5","volume":"9","author":"D-P Chen","year":"2019","unstructured":"Chen, D.-P., Chang, S.-W., Wang, P.-N., Hus, F.-P. & Tseng, C.-P. Association between single nucleotide polymorphisms within HLA region and disease relapse for patients with hematopoietic stem cell transplantation. Sci. Rep. 9, 13731 (2019).","journal-title":"Sci. Rep."},{"key":"37592_CR49","doi-asserted-by":"publisher","first-page":"609","DOI":"10.3389\/fphar.2019.00609","volume":"10","author":"D Liao","year":"2019","unstructured":"Liao, D., Wang, M., Liao, Y., Li, J. & Niu, T. A review of efficacy and safety of checkpoint inhibitor for the treatment of acute myeloid leukemia. Front. Pharm. 10, 609\u2013609 (2019).","journal-title":"Front. Pharm."},{"key":"37592_CR50","doi-asserted-by":"publisher","first-page":"2255","DOI":"10.1056\/NEJMoa1609279","volume":"375","author":"E Tran","year":"2016","unstructured":"Tran, E. et al. T-cell transfer therapy targeting mutant KRAS in cancer. N. Engl. J. Med. 375, 2255\u20132262 (2016).","journal-title":"N. Engl. J. Med."},{"key":"37592_CR51","doi-asserted-by":"publisher","first-page":"288","DOI":"10.1158\/2326-6066.CIR-14-0207","volume":"3","author":"DB Johnson","year":"2015","unstructured":"Johnson, D. B. et al. Impact of NRAS mutations for patients with advanced melanoma treated with immune therapies. Cancer Immunol. Res. 3, 288\u2013295 (2015).","journal-title":"Cancer Immunol. Res."},{"key":"37592_CR52","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1038\/s41591-018-0321-2","volume":"25","author":"Y Xu","year":"2019","unstructured":"Xu, Y. et al. Translation control of the immune checkpoint in cancer and its therapeutic targeting. Nat. Med. 25, 301\u2013311 (2019).","journal-title":"Nat. Med."},{"key":"37592_CR53","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-022-34000-6","volume":"13","author":"D Zimmerli","year":"2022","unstructured":"Zimmerli, D. et al. MYC promotes immune-suppression in triple-negative breast cancer via inhibition of interferon signaling. Nat. Commun. 13, 6579 (2022).","journal-title":"Nat. Commun."},{"key":"37592_CR54","doi-asserted-by":"publisher","first-page":"872","DOI":"10.1158\/2159-8290.CD-19-0620","volume":"10","author":"N Muthalagu","year":"2020","unstructured":"Muthalagu, N. et al. Repression of the type I interferon pathway underlies MYC- and KRAS-dependent evasion of NK and B cells in pancreatic ductal adenocarcinoma. Cancer Discov. 10, 872\u2013887 (2020).","journal-title":"Cancer Discov."},{"key":"37592_CR55","doi-asserted-by":"publisher","first-page":"2849","DOI":"10.1182\/blood-2011-03-345165","volume":"118","author":"SW Lane","year":"2011","unstructured":"Lane, S. W. et al. Differential niche and Wnt requirements during acute myeloid leukemia progression. Blood 118, 2849\u20132856 (2011).","journal-title":"Blood"},{"key":"37592_CR56","doi-asserted-by":"publisher","first-page":"4226","DOI":"10.1093\/emboj\/16.14.4226","volume":"16","author":"C Lavau","year":"1997","unstructured":"Lavau, C., Szilvassy, S. J., Slany, R. & Cleary, M. L. Immortalization and leukemic transformation of a myelomonocytic precursor by retrovirally transduced HRX-ENL. EMBO J. 16, 4226\u20134237 (1997).","journal-title":"EMBO J."},{"key":"37592_CR57","doi-asserted-by":"publisher","first-page":"818","DOI":"10.1038\/nature04980","volume":"442","author":"VK Andrei","year":"2006","unstructured":"Andrei, V. K. et al. Transformation from committed progenitor to leukaemia stem cell initiated by MLL\u2013AF9. Nature 442, 818 (2006).","journal-title":"Nature"},{"key":"37592_CR58","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1093\/bioinformatics\/bts635","volume":"29","author":"A Dobin","year":"2013","unstructured":"Dobin, A. et al. STAR: ultrafast universal RNA-seq aligner. Bioinformatics 29, 15\u201321 (2013).","journal-title":"Bioinformatics"},{"key":"37592_CR59","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1093\/bioinformatics\/btp616","volume":"26","author":"MD Robinson","year":"2010","unstructured":"Robinson, M. D., McCarthy, D. J. & Smyth, G. K. edgeR: a Bioconductor package for differential expression analysis of digital gene expression data. Bioinformatics 26, 139\u2013140 (2010).","journal-title":"Bioinformatics"},{"key":"37592_CR60","doi-asserted-by":"publisher","first-page":"15545","DOI":"10.1073\/pnas.0506580102","volume":"102","author":"A Subramanian","year":"2005","unstructured":"Subramanian, A. et al. Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc. Natl Acad. Sci. USA 102, 15545\u201315550 (2005).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"37592_CR61","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1038\/ng1180","volume":"34","author":"VK Mootha","year":"2003","unstructured":"Mootha, V. K. et al. PGC-1\u03b1-responsive genes involved in oxidative phosphorylation are coordinately downregulated in human diabetes. Nat. Genet. 34, 267 (2003).","journal-title":"Nat. Genet."}],"container-title":["Nature Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41467-023-37592-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-023-37592-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-023-37592-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,4,14]],"date-time":"2023-04-14T15:03:14Z","timestamp":1681484594000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41467-023-37592-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,4,14]]},"references-count":61,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["37592"],"URL":"https:\/\/doi.org\/10.1038\/s41467-023-37592-9","relation":{"has-preprint":[{"id-type":"doi","id":"10.1101\/2023.02.08.527448","asserted-by":"object"}]},"ISSN":["2041-1723"],"issn-type":[{"value":"2041-1723","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,4,14]]},"assertion":[{"value":"12 October 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 March 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 April 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"S.W.L. has participated in advisory boards for Celgene, Novartis and Janssen, and has received research funding from Janssen and Celgene\/ Bristol Myers Squibb for unrelated projects. G.R.H. has consulted for Generon Corporation, NapaJen Pharma, iTeos Therapeutics, Neoleukin Therapeutics and has received research funding from Compass Therapeutics, Syndax Pharmaceuticals, Applied Molecular Transport, Serplus Technology, Heat Biologics, Laevoroc Oncology, Genentech and iTeos Therapeutics. F.S.F.G. is a consultant and has a funded research agreement with Biotheus Inc. The remaining authors declare no other competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"2155"}}